Biotech giant Aventis is expected to reveal today that it is in exclusive talks with German firm Bayer over the sale of its Aventis CropScience operations.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The French/German group has been trying to sell the business for some time now but only decided on a valuation last months, when it slapped on a price tag of around US$3bn.
Market watchers may also hear today whether Germany’s Schering, which owns a minority stake in CropScience, has decided to sell and participate in the talks.